Pharmacy was built around scale. A manufacturer develops one medication, FDA approves it, and the same product can eventually reach thousands or millions of patients.
Precision medicine has already started changing that model. Biomarkers, genetic testing, and molecular diagnostics can divide a disease into smaller groups and identify the patients most likely to benefit from a particular treatment.
Now FDA is preparing for something even more individualized.
On October 27, the agency released draft guidance describing a regulatory pathway for individualized human genome-editing products used to treat rare genetic diseases. In these programs, the genome-editing product itself could vary from one patient to another because different patients may carry different disease-causing genetic variants. FDA is proposing a framework that could allow multiple patient-specific versions to exist under a single Biologics License Application, or BLA, when those versions stay within predefined scientific boundaries.
This is still draft guidance, not final policy. FDA is accepting comments through November 27, 2026. However, the direction is remarkable.
For most of pharmacy history, we have asked which drug is right for the patient.
In some areas of medicine, the future question may become: how do we build the therapy around this patient?
FDA is preparing for therapies that can change from patient to patient
Some rare genetic diseases create an unusual development problem. Two patients may have the same disease, yet the exact disease-causing mutation can differ between them.
That matters for genome editing.
A therapy designed to correct one patient’s mutation may require a different editing component for another patient. Under the traditional development model, creating a slightly different product for every mutation could make the regulatory path extremely difficult, especially when only a handful of patients share each variant.
FDA’s draft guidance proposes a way to manage that variation.
The agency introduced a concept called the Individualized Feature Space, or IFS. It defines the boundaries within which certain features of a genome-editing product could vary while the different versions remain part of the same licensed product.
For example, the targeting sequence used by a genome-editing system might change so it can recognize a different pathogenic mutation. Other important parts of the product would remain consistent, such as the delivery system, formulation, or cell type. FDA also expects the variants covered by one BLA to share the same mechanism of action and intended editing outcome.
That is a very different way to think about a pharmaceutical product.
One approval could potentially support many patient-specific variants
The most important part of the proposal comes after approval.
If a new patient needs a slightly different version of the therapy, the manufacturer may not need to restart the entire clinical-development program. FDA says a new variant that falls within the established Individualized Feature Space could potentially be added to the existing BLA through a streamlined process.
The manufacturer would still need evidence.
FDA expects laboratory testing to demonstrate appropriate activity and evaluate risks such as unintended genome editing. The agency could then rely on the clinical evidence that supported the original license together with the new variant’s laboratory data. If the patient-specific version stays within the approved scientific boundaries, additional clinical trials may not be necessary.
That distinction is important.
FDA is not proposing that companies create unlimited customized therapies under one approval. The framework depends on predefined limits, common mechanisms, validated manufacturing processes, and evidence showing that each new variant remains safe and active.
Still, the regulatory concept is striking.
The approved product may no longer be one completely identical therapy.
It may become a platform capable of producing multiple individualized versions.
The medication itself starts to become a platform
Traditional pharmacy works well with a standardized-product mindset.
One NDC represents a defined product. Manufacturing produces consistent units. Distribution moves those units through the supply chain. Prescribers choose among approved products, and pharmacies manage storage, dispensing, counseling, and monitoring.
Individualized genome editing challenges that mental model.
The therapeutic platform may remain consistent while one component changes based on the patient’s genetic mutation. The patient therefore becomes part of the product-definition process in a way that is uncommon with conventional medications.
That creates new questions throughout healthcare.
How is the patient’s genetic variant confirmed? How does the manufacturer ensure the correct individualized product reaches the correct patient? How do treatment centers distinguish one patient’s version from another? What information follows the therapy through manufacturing, distribution, preparation, and administration?
FDA’s guidance already addresses issues such as manufacturing, safety testing, product naming, identification, and labeling. Those topics become especially important when different versions of the therapy exist within one regulatory framework.
This is where the Future of Pharmacy story begins.
As the treatment becomes more individualized, the system surrounding it has to become more precise too.
The pharmacy challenge moves far beyond dispensing
Imagine a patient with an ultra-rare genetic disorder who may qualify for an individualized genome-editing therapy.
Before treatment begins, the healthcare system may need to confirm the molecular diagnosis and specific genetic variant. The manufacturer may need to produce or validate the appropriate version of the therapy. A specialized center may have to coordinate administration.
Meanwhile, someone must manage payer approval, treatment scheduling, handling requirements, patient education, safety monitoring, and long-term follow-up.
Each step creates opportunities for failure.
The wrong genetic information cannot follow the patient. The wrong product variant cannot reach the treatment center. Storage and handling requirements cannot be missed. Coverage issues may need resolution before treatment. Long-term outcomes may require tracking for years.
For a conventional medication, pharmacy often focuses heavily on the product itself.
For individualized therapies, medication expertise may increasingly include the entire system required to get one highly specialized treatment to one specific patient safely.
That is a very different picture of pharmacy practice.
The future pharmacist may become a therapy navigator
This is why the pharmacist’s role around advanced therapies could become broader.
A pharmacist working in this environment may need to understand the treatment’s mechanism, but that may only be the starting point. They may also need familiarity with genomics, biomarkers, specialty distribution, payer requirements, treatment-center logistics, adverse-event monitoring, and long-term follow-up.
Different pharmacists could participate at different points.
One may work inside a health system preparing for cell and gene therapies. Another may work in specialty pharmacy or patient access. A pharmacist inside a biotechnology company could support medical affairs, clinical development, regulatory strategy, pharmacovigilance, or patient services.
Others may work on outcomes data, reimbursement, value-based contracting, or treatment operations.
The common theme is coordination.
The more complicated the therapy becomes, the more important it becomes to have people who can understand both the treatment and the healthcare system around it.
Pharmacists are naturally positioned at that intersection because medication knowledge has always required connecting science with real-world use.
Access may be as difficult as developing the therapy
FDA’s announcement arrived alongside another important development from CMS.
The agency said it plans to broaden its Cell and Gene Therapy Access Model beyond sickle cell disease. The voluntary model allows CMS to negotiate outcomes-based agreements with manufacturers on behalf of state Medicaid programs. Those agreements can tie part of the payment for expensive therapies to what happens to patients after treatment.
The model initially focused on gene therapies for sickle cell disease. CMS says participating programs now include 32 states, the District of Columbia, and Puerto Rico. The agency plans to invite manufacturers of therapies for additional conditions to participate and intends to release a new Request for Applications in the coming months.
These two announcements belong together.
FDA is trying to create a regulatory pathway for increasingly individualized treatments.
CMS is simultaneously asking how public insurance programs can afford and manage access to extremely expensive cell and gene therapies.
Developing the science solves only part of the problem.
Healthcare still has to figure out how to pay for it.
Outcomes-based payment creates another layer of pharmacy complexity
Traditional medication payment is relatively simple conceptually. A payer reimburses for a drug when it is dispensed or administered.
A multimillion-dollar gene therapy creates a harder question.
What if the treatment is expected to produce benefits that last for years? What if the patient does not achieve the expected outcome? What happens if the patient moves to another insurance plan after treatment?
Outcomes-based agreements attempt to connect part of the drug’s payment to what happens after therapy. CMS’s model allows the federal government to negotiate key terms with manufacturers, including pricing discounts and outcomes-based rebates, which participating state Medicaid programs can then use.
That creates an enormous data requirement.
Someone has to define the outcome. Someone has to measure it. The health system must collect the necessary information. Payers and manufacturers need enough data to determine whether the agreement’s conditions were met.
Pharmacy expertise may increasingly intersect with this world too.
Medication use is no longer just a clinical event. For some advanced therapies, it can also trigger years of clinical, operational, financial, and data obligations.
The pharmacist of the future may need to understand the contract around the therapy
This is a career signal that pharmacy students rarely hear about.
A pharmacist working with advanced therapies may eventually need to understand far more than pharmacology.
They may need to know why a genetic test qualifies a patient for treatment. They could need familiarity with how a specialty product moves through limited distribution. Some roles may require knowledge of Medicaid coverage, manufacturer agreements, reimbursement, and outcomes tracking.
Others could involve registries, real-world evidence, long-term safety, or coordination between treatment centers and manufacturers.
That does not mean every pharmacist needs to become a genomic medicine expert.
It means that medication expertise is expanding.
As therapies become more sophisticated, the surrounding jobs become more specialized too.
Search current openings in cell and gene therapy and you will find functions in market access, clinical operations, medical affairs, patient services, regulatory affairs, quality, manufacturing, specialty distribution, HEOR, reimbursement, and treatment-center operations.
Many of those roles may never contain the word pharmacist in the title.
A PharmD can still be valuable inside them.
Individualized medicine changes the meaning of scale
One of the most interesting business questions is what happens to pharmaceutical economics when fewer patients share the same exact product.
Traditional drug development depends heavily on scale. A company spends enormous amounts developing a therapy, then distributes the same product across a large market.
Rare disease already challenges that model.
Individualized genome editing takes the challenge further.
The scientific platform may serve many people, but each patient’s therapy could require some individualized design or testing. Manufacturers therefore need systems that can personalize part of the product without rebuilding the development program from zero every time.
FDA’s proposed Individualized Feature Space is an attempt to create regulatory scale around scientific personalization.
That concept could become very important.
Instead of scaling one identical molecule, the company scales the platform, manufacturing process, evidence base, assays, and regulatory framework that allow it to create many related therapies.
The product becomes individualized.
The infrastructure becomes scalable.
This could create a new category of medication safety
Patient-specific products also introduce unusual safety questions.
Traditional medication safety already depends on getting the right drug to the right patient.
Individualized therapies may add another layer: the correct version of the drug must reach the correct patient.
That could make product identification, chain of custody, documentation, labeling, and verification even more important.
FDA’s draft guidance recognizes this issue. It discusses naming and identification for product variants in addition to manufacturing and safety testing.
Pharmacists should pay attention to that distinction.
We already build systems around the five rights of medication use. Advanced therapies could require those principles to extend into molecular identity.
For some treatments, verifying the patient’s diagnosis may not be enough. The care system may also need to verify that the exact therapeutic variant matches the genetic information that produced it.
That is precision medicine becoming operational.
Long-term monitoring may become part of the therapy itself
Individualized genome editing also raises another issue: the treatment may happen once, but the care journey may continue for years.
Genome-editing therapies can create durable biological changes. Therefore, long-term safety and outcome monitoring may play an important role in understanding how these treatments perform outside clinical trials.
That creates work across pharmacovigilance, specialty care, registries, data management, treatment centers, and payer programs.
CMS’s growing interest in outcomes-based agreements reinforces the same idea.
The health system cannot simply document that the therapy was administered and move on.
Someone may need to know whether it worked months or years later.
For pharmacists, that creates another evolution in how we think about a medication episode.
The dispensing or administration event may become the beginning of the evidence journey rather than the end.
That creates room for pharmacists who understand both medications and longitudinal outcomes.
Follow the ecosystem, not the title
For pharmacists curious about this future, the first step is not finding a certification.
It is understanding the ecosystem.
Start with three terms: genome editing, individualized therapy, and outcomes-based agreement.
Then search for jobs involving cell and gene therapy without filtering for pharmacist.
Look at what appears.
You may find positions in gene-therapy operations, medical affairs, clinical development, patient access, regulatory strategy, market access, specialty pharmacy, quality, reimbursement, clinical operations, manufacturing, pharmacovigilance, and health economics.
Read the job descriptions.
Which roles value clinical knowledge? Which require regulatory experience? Where does genomics appear? Who handles patient identification? Which teams manage treatment-center readiness? Who owns reimbursement? Who measures long-term outcomes?
That exercise will reveal something important.
The career opportunities around a medication can become much larger than the job of dispensing it.
Ask what happens around one patient
There is another useful exercise.
Imagine one patient with a rare genetic disease who has just been identified as a candidate for an individualized genome-editing therapy.
Map everything that has to happen next.
Someone confirms the genetic diagnosis. Someone determines whether the patient’s mutation fits the therapeutic platform. The appropriate product variant has to be manufactured and tested. Coverage has to be secured.
The treatment center must prepare. The therapy needs appropriate storage, handling, and administration. The patient and family need education. Safety must be monitored. Outcomes may need to be documented long after treatment.
Now look at the map and ask which parts require medication expertise.
Then ask which parts pharmacists could realistically own.
That is a more useful way to think about the future of the profession than trying to guess which traditional pharmacy job will grow fastest.
Follow the therapy.
The jobs often reveal themselves around it.
The more individualized medicine becomes, the more coordination it requires
There is an interesting paradox in precision medicine.
The treatment becomes more individualized, but delivering it requires more people and systems to work together.
A patient-specific therapy may depend on genetic laboratories, biotechnology companies, FDA, payers, Medicaid programs, specialty distributors, treatment centers, physicians, nurses, pharmacists, data teams, and long-term registries.
The medicine becomes more precise.
The healthcare infrastructure becomes more complicated.
That complexity creates an opportunity for pharmacists.
Medication expertise has always involved more than memorizing drugs. Pharmacists understand how treatments move from evidence into real patients. We understand dosing, safety, interactions, access barriers, distribution, monitoring, and the operational reality of medication use.
Those skills become more valuable when the medication is difficult to deliver.
Advanced therapies simply raise the difficulty.
The future prescription may not look like a prescription at all
FDA’s October 27 guidance is only a draft. It does not mean individualized genome-editing therapies will suddenly become common, nor does it guarantee that every patient-specific variant will move through one streamlined approval process.
The scientific boundaries matter. Manufacturing matters. Safety testing matters. FDA review still matters.
However, the agency is now formally describing a regulatory pathway for a world in which a licensed therapeutic platform may generate different versions for different patients.
That should make pharmacists think bigger.
Pharmacy began with standardized products. Precision medicine narrowed those products to increasingly specific populations.
Individualized genome editing could move us another step forward.
One therapeutic platform.
One patient.
One genetic variant.
Potentially one version of the treatment designed around that biology.
If medicine continues moving in that direction, the future pharmacist will need to understand much more than the drug sitting on the shelf.
They may need to understand the patient’s genome, the therapeutic platform, the manufacturing pathway, the access model, the financial contract, and the years of monitoring that follow treatment.
The more individualized medicine becomes, the more important medication expertise may become.
The expertise will simply look very different from the pharmacy many of us were trained to imagine.
Resources & Citations
- U.S. Department of Health and Human Services. “FDA and CMS Announce New Steps to Advance Gene Therapies and Expand Access for Patients with Rare Diseases.” October 27, 2026. The announcement describes FDA’s draft framework for individualized genome-editing products and CMS’s planned expansion of the Cell and Gene Therapy Access Model beyond sickle cell disease.
- U.S. Food and Drug Administration. “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management.” Draft Guidance for Industry, October 2026. The guidance explains how multiple individualized product variants could fall within one BLA, how FDA proposes defining an Individualized Feature Space, and how new variants could be added after licensure. Comments are due November 27, 2026.
- Centers for Medicare & Medicaid Services. “Innovation Insight: CGT Access Model Builds on Initial Success with New Therapies to Be Added Following Manufacturer Negotiations.” October 27, 2026. CMS announced plans to broaden the Cell and Gene Therapy Access Model beyond sickle cell disease and invite manufacturers of additional therapies to participate in CMS-led outcomes-based agreement negotiations.
- Centers for Medicare & Medicaid Services. “Cell and Gene Therapy Access Model.” Current program overview. CMS describes the voluntary model, outcomes-based agreements, state participation, payment structure, and its initial focus on gene therapies for sickle cell disease.
- Federal Register. “Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability.” Published October 28, 2026, 91 FR 67838. The notice confirms the single-BLA framework and public comment period.
- AABB. “FDA Releases New Draft Guidance on Individualized Human Genome Editing Products.” October 28, 2026. The regulatory update summarizes FDA’s proposed pathway for licensing patient-specific genome-editing variants while maintaining standards for safety, potency, quality, manufacturing, and product identification.